03:47 PM EST - Intellipharmaceutics International Inc. : Today reported revenue related to the Company's license and commercialization agreement with Par Pharmaceutical, Inc. in the three months ended August 31, 2015, was $0.8 million versus $1.1 million for the three months ended August 31, 2014. The Company recorded net loss for the three months ended August 31, 2015 of $1.9 million or $0.08 per common share, compared with a net loss of $1.7 million or $0.07 per common share for the three months ended August 31, 2014. All amounts in U.S. dollars. Intellipharmaceutics International Inc.
shares T.I are trading down $0.12 at $2.30.
